Experts suggest that if the price differential is marginal, many patients may prefer the innovators brand due to its well-established efficacy, a trend previously observed with Novos insulin injectables
Unopened GLP1 pens must stay refrigerated (36F to 46F)
comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
As use of these drugs continues to expand, it becomes increasingly important to understand their real-world benefits and risks across populations. Guo conducted this research in collaboration with William Donahoo, M.D., clinical professor and chief of the UF Health Division of Endocrinology, Diabetes and Metabolism, and Steven T DeKosky, M.D., deputy director of the McKnight Brain Institute and professor of Alzheimer's research, neurology and neuroscience in the UF Department of Neurology
Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol
The brand-name pricing is substantially higher at around $1,399 per month but having the option means patients can switch if regulatory changes affect compounding availability
